- Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
- Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
- Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
- Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
- Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
- Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
- Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
- Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
- Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
- Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
More ▼
Key statistics
On Monday, Connect Biopharma Holdings Ltd (CNTB:NMQ) closed at 1.35, 152.48% above the 52 week low of 0.5347 set on Sep 21, 2023.
52-week range
Open | 1.54 |
---|---|
High | 1.54 |
Low | 1.28 |
Bid | 1.36 |
Offer | 1.54 |
Previous close | 1.35 |
Average volume | 90.44k |
---|---|
Shares outstanding | 55.10m |
Free float | 31.38m |
P/E (TTM) | -- |
Market cap | 74.39m USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 22 2024 21:00 BST.
More ▼